Harrow (NASDAQ:HROW) Downgraded by Zacks Research to Strong Sell

Zacks Research cut shares of Harrow (NASDAQ:HROW) from a hold rating to a strong sell rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

A number of other analysts have also commented on HROW. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. HC Wainwright raised their price objective on shares of Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday. William Blair reissued an “outperform” rating on shares of Harrow in a report on Tuesday. LADENBURG THALM/SH SH upped their price target on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Finally, Cantor Fitzgerald dropped their price target on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $71.14.

Harrow Price Performance

Shares of NASDAQ:HROW traded down $2.87 during trading on Tuesday, hitting $36.35. 1,251,536 shares of the company were exchanged, compared to its average volume of 702,787. Harrow has a 1-year low of $20.85 and a 1-year high of $54.85. The company has a market capitalization of $1.35 billion, a P/E ratio of -213.81 and a beta of 0.05. The company has a quick ratio of 2.52, a current ratio of 2.20 and a debt-to-equity ratio of 4.67. The business’s 50 day moving average is $48.19 and its 200-day moving average is $43.76.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.23). The firm had revenue of $89.09 million for the quarter, compared to analyst estimates of $88.42 million. Harrow had a negative net margin of 1.89% and a positive return on equity of 36.51%. Equities analysts forecast that Harrow will post -0.53 earnings per share for the current year.

Institutional Investors Weigh In On Harrow

A number of institutional investors have recently modified their holdings of HROW. Virtu Financial LLC acquired a new stake in shares of Harrow during the fourth quarter worth $702,000. Invesco Ltd. boosted its position in Harrow by 35.7% during the fourth quarter. Invesco Ltd. now owns 145,406 shares of the company’s stock valued at $7,125,000 after acquiring an additional 38,264 shares during the last quarter. Occudo Quantitative Strategies LP bought a new stake in Harrow during the fourth quarter valued at $801,000. Cetera Investment Advisers grew its holdings in Harrow by 2.6% during the 4th quarter. Cetera Investment Advisers now owns 23,256 shares of the company’s stock worth $1,140,000 after acquiring an additional 597 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Harrow by 4.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,412 shares of the company’s stock worth $1,246,000 after acquiring an additional 1,161 shares in the last quarter. 72.76% of the stock is owned by institutional investors.

Trending Headlines about Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Company-reported momentum: Harrow posted record 2025 results and set a 2026 revenue goal of $350M–$365M, highlighting sales-force expansion and product pipeline progress that support medium-term growth expectations. Read More.
• Positive Sentiment: Bullish analyst views remain: HC Wainwright maintains a “Buy” rating and recently raised its price target to $70, reflecting continued analyst confidence in upside from current levels. Read More.
• Positive Sentiment: Cantor Fitzgerald still overweight: Cantor cut its target slightly but remains “Overweight” with a $91 target, signaling some firms see large upside versus the stock’s current price. Read More.
• Neutral Sentiment: Investor outreach scheduled: Management will present at the Leerink Partner’s 2026 Global Healthcare Conference (Mar 10), giving investors another opportunity for management guidance and pipeline detail. Read More.
• Negative Sentiment: Quarterly EPS miss and reaction: Q4 EPS came in at $0.17 versus roughly $0.40 expected; the market reacted with a gap-down in the stock after the print. That EPS miss is the most direct catalyst for today’s weakness. Read More.
• Negative Sentiment: Analyst estimate cuts and downgrades: Zacks downgraded Harrow to “Strong Sell,” and HC Wainwright trimmed its EPS forecasts for Q3 and Q4 (reducing Q4 from $0.51 to $0.40 and Q3 from $0.29 to $0.20), which pressures sentiment despite HC Wainwright’s Buy rating. Read More. and Read More.
• Negative Sentiment: Fundamental concerns flagged by some analysts: Independent write-ups (Seeking Alpha) highlight low margins, high leverage and rising interest costs that could constrain free cash flow and make growth more expensive — a narrative contributing to downgrade activity. Read More.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.